About Jeffrey Hung
Jeffrey Hung is co-founder and chief executive officer of Accufy Diagnostics (AccufyDx). The company works on NGS-based multiomic analysis for MRD diagnosis. Hung co-invented the company's tagging library preparation and target enrichment methods for NGS. He is also chief commercial advisor at uBriGene, a company in cell and gene therapy manufacturing.
Earlier, Hung served as general manager and chief commercial officer at Vigene Biosciences. Vigene is a gene delivery company that CRL acquired in July 2021. As general manager of its GMP business, he led Vigene's 2016 purchase of Omnia Biologics. Before Vigene, he was a senior executive at GenScript, a gene synthesis and life science service company. He helped grow GenScript to its December 2015 IPO. He was also part of the management team at SABiosciences, which was sold to QIAGEN in 2010. He holds a PhD from Cornell University, an MBA from UC Berkeley and a BS from Peking University.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Jeffrey Hung in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jeffrey Hung works with at each company, as listed on that company's latest Form D.